ClinicalTrials.gg
CompletedNCT00709761Updated Mar 26, 2019Results posted

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

A Phase 2 interventional study of Lapatinib/nab-Paclitaxel in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
40th of 114
60 · median 35
Started
2008
with 14 others
Phase 2
60 of 114
none open now
Registered
56th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 40th largest by enrollment, is one of 15 that started in 2008, is one of 60 in phase 2, and was the 56th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Sixty subjects were to be enrolled in the study. Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib (1000 mg once daily). Subjects were to receive treatment until disease progression or withdrawal from the study. The primary objective of this study was to evaluate overall tumor response rate of lapatinib in combination with nab-paclitaxel administered in women with ErbB2 overexpressing MBC who received no chemotherapeutic regimen in the metastatic setting. Secondary objectives included progression-free survival, overall survival, duration of response, time to response and time to progression and safety. Safety and efficacy assessments were to be performed at 8 and 12 week intervals, and at the end of treatment.

Subject: Metastatic Breast Cancer, ErbB2, First-line therapy, Lapatinib, Nab-paclitaxel

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • Erbb2
  • ABRAXANE
  • MBC
  • first or second line therapy
  • Metastatic Breast Cancer
  • TYKERB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject was eligible for inclusion in this study only if all of the following criteria apply:

  • Subjects must have confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. Where the disease was restricted to a solitary lesion, the neoplastic nature of the lesion should have been confirmed by cytology or histology.
  • Documented amplification of ErbB2 3+ by immunohistochemistry or a positive score (>2.2) by FISH using a local laboratory result (which was considered sufficient in this study with no further verification by a central laboratory).
  • Subjects must have received no more than one prior chemotherapeutic regimen in the setting.
  • If a taxane had been administered in the , adjuvant or metastatic setting, progression must have occurred ≥12 months after completion of this treatment.
  • Prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. Radiotherapy given in the metastatic setting, prior to initiation of study medication, was allowed to a limited area (e.g., palliative therapy and involving less than 25% of bone marrow), if it was not the sole site of disease. Subjects must have completed radiation treatment and recovered from all acute radiation treatment related toxicities (e.g., bone marrow suppression) prior to commencement of combination treatment.
  • The subject must have received all prior chemotherapy treatment at least 4 weeks prior to enrollment in this study and must have recovered from all related toxicities. Subjects who have received weekly dose of prior chemotherapy e.g. gemcitabine or capecitabine may enroll 2 to 3 weeks after cessation of treatment provided that they have recovered from all related toxicities.
  • Prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. The subject must have received all prior trastuzumab treatment at least 4 weeks prior to enrollment in this study and must have recovered from all related toxicities.
  • Prior endocrine therapy was permitted in the neoadjuvant or adjuvant or metastatic setting. The subject must have received all prior endocrine treatment at least 1 week prior to enrollment in this study and must have recovered from all related toxicities.
  • Prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. Subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed if it had been 1 year or greater since definitive surgery.
  • Subjects must have had , according to (RECIST) guidelines; defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter [LD] to be recorded) by mammogram, ultrasound or physical exam [Therasse, 2000].
  • Subjects with liver metastases or stable chronic liver disease were permitted into the study.
  • Women ≥18 years of age:
  • Non- (i.e., women with functioning ovaries who had a current documented tubal ligation or hysterectomy, or women who were ); or
  • Child-bearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category included women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate. These subjects must provided a negative serum pregnancy test at Screening and agree to 1 of the following:
  • Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication; or
  • Consistent and correct use of one of the following acceptable methods of :
  • Male partner who was sterile prior to the female subject's entry into the study and was the sole sexual partner for that female subject.
  • Implants of levonorgestrel.
  • Injectable progestogen.
  • Any intrauterine device with a documented failure rate of less than 1% per year.
  • Oral contraceptives (either combined or progestogen only).
  • Barrier methods, including diaphragm or condom with a spermicide.
  • Considered by the Investigator to have a of ≥6 months.
  • Performance Status (PS) of 0 or 1 ( ≥80%) [Oken, 1982].
  • Subjects must have had normal organ and marrow function as below:
  • Hematologic
  • ≥1.5 × 10\^9/L
  • ≥9 g/dL
  • ≥100 × 10\^9/L
  • Hepatic
  • Serum ≤ (ULN)
  • ≤3 × ULN without liver metastases and alanine aminotransferase ≤5 × ULN if documented liver metastases
  • Renal
  • Serum creatinine ≤1.5 mg/dL
  • OR -
  • Calculated ≥40 mL/min
  • Subjects must have had a cardiac of >50% as measured by echocardiogram (ECHO) or multigated acquisition scan (MUGA) and within the institutional range of normal.
  • Subjects with stable central nervous system metastases (stable for at least 3 months) as confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) or evidence of were eligible only if they were not taking or enzyme-inducing anticonvulsants.
  • Subject must have been free of gastrointestinal diseases that impede swallowing and retaining of oral medications.
  • Signed, prior to registration.
  • Bisphosphonate therapy for bone metastases was allowed; however, treatment must be initiated prior to the first dose of study medication. Prophylactic use of bisphosphonates in subjects without bone disease, except for the treatment of osteoporosis, was not permitted.
  • Subjects whose disease was estrogen receptor + and/or progesterone receptor + or unknown status were included in the study if they met the following criteria:
  • They had symptomatic visceral disease that required chemotherapy.
  • Significant visceral organ tumor burden
  • The disease was considered by the Investigator to be progressing rapidly or life threatening.
  • Subjects who have received prior endocrine therapy and who were no longer benefiting from this therapy.

Exclusion criteria

Exclusion Criteria:

A subject was not be eligible for inclusion in this study if any of the following criteria apply:

  • Subjects who received more than one prior chemotherapeutic regimen in the setting
  • Subjects taking treatment with medications provided in the list of restricted medications and substances in the drug information section for lapatinib were not eligible for the study. This included -positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib.
  • Prior treatment with lapatinib.
  • Concurrent anticancer or concomitant radiotherapy treatment;
  • Concurrent treatment with prohibited medications;
  • Use of an drug within 30 days or 5 half-lives, whichever was longer, preceding the first dose of investigational treatment, or, concurrent treatment with an investigational agent or participation in another clinical trial involving investigational agents.
  • Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or nab-paclitaxel or ;
  • Known history of uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements.
  • Had active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.
  • Pregnant or lactating females at any time during the study (due to the potential teratogenic or abortifacient effects of lapatinib and breastfeeding).
  • Subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication, including; malabsorption syndrome, a requirement for iv alimentation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis).
  • Peripheral neuropathy of Grade 2 or greater.
  • Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.
  • History of prior . However, subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery.
  • or rendering of .

Other Eligibility Criteria Considerations:

  • To assess any potential impact on subject eligibility with regard to safety, the Investigator must refer to the following document(s) for detailed information regarding warnings, precautions, , AEs, and other significant data pertaining to the investigational product(s) being used in this study: Clinical Investigator's Brochure (IB), SPM, and the nab-paclitaxel Product Label.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Single Arm

    Single arm combination therapy of Lap and NabPaclitaxel combination

    Drug: Lapatinib/nab-Paclitaxel

Interventions

  • DrugLapatinib/nab-Paclitaxel

    Drug pages: Lapatinib · Albumin-Bound Paclitaxel

    This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).

06

What researchers measure

Primary outcomes

  1. Overall Tumor Response (OR)

    OR was defined as the percentage of participants experiencing either a confirmed complete response (CR) or a confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0. CR is defined as the disappearance of all lesions (target and/or non-target). PR is defined as at least a 30% decrease in the sum of the longest dimensions (LD) of target lesions taking as a reference the baseline sum LD, with non-target lesions not increased or absent.

    Time frame: Start of treatment to disease progression or death or discontinuation from study or at least 28 days after last dose (up to Week 131)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the start of treatment until death due to any cause. For participants who did not die, time to death was censored at the time of last contact. OS could not be analyzed because only 13 participants had died as of data cut off, and data were not mature (greater than 75% of the participants were censored for the endpoint).

    Time frame: Start of treatment to death (up to Week 131)

  2. Duration of Response (DOR)

    DOR was defined for the subset of participants who showed a confirmed CR or PR, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.

    Time frame: First documented response (CR or PR) to disease progression or death (up to Week 131)

  3. Time to Response (TTR)

    TTR was defined for the subset of participants who showed a confirmed CR or PR, as the time from the start of treatment until the first documented evidence of CR or PR (whichever status was recorded first).

    Time frame: Start of treatment to first documented response (CR or PR) (up to Week 131)

  4. Time to Progression (TTP)

    TTP was defined as the interval between the start of treatment until the earliest date of disease progression or death due to breast cancer.

    Time frame: Start of treatment to disease progression or death (up to Week 131)

  5. Progression-Free Survival (PFS)

    PFS was defined as the time from the start of treatment until the earliest date of disease progression or death due to any cause, if sooner.

    Time frame: Start of treatment to disease progression or death (up to Week 131)

07

Results

Posted Nov 22, 2011

Participant flow

Summary of subject disposition table is on the intent-to-treat (ITT) population. The ITT population comprised of all subjects who received at least 1 dose of investigational product. The ITT population, which is the same as the actually treated population, is used for all the analyses of EOS reporting.

Participant flow — Overall Study
MilestoneLapatinib 1000 mg + Nab-Paclitaxel
Started60
Completed33
Not completed27
Withdrew: Withdrawal by subject8
Withdrew: Study closed/terminated17
Withdrew: Lost to follow-up2

Outcome measures

PrimaryOverall Tumor Response (OR)

OR was defined as the percentage of participants experiencing either a confirmed complete response (CR) or a confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0. CR is defined as the disappearance of all lesions (target and/or non-target). PR is defined as at least a 30% decrease in the sum of the longest dimensions (LD) of target lesions taking as a reference the baseline sum LD, with non-target lesions not increased or absent.

Time frame:
Start of treatment to disease progression or death or discontinuation from study or at least 28 days after last dose (up to Week 131)
Reported as:
Number · percentage of participants
Overall Tumor Response (OR)
percentage of participantsLapatinib 1000 mg + Nab-Paclitaxel
Overall Tumor Response (OR)53
Statistical analysis
  • Lapatinib 1000 mg + Nab-Paclitaxel · Percentage of participants: 53.0 · 95% CI 40.7 to 66.0The estimation parameter represents the percentage of participants experiencing either a CR or a PR.
SecondaryOverall Survival (OS)

OS was defined as the time from the start of treatment until death due to any cause. For participants who did not die, time to death was censored at the time of last contact. OS could not be analyzed because only 13 participants had died as of data cut off, and data were not mature (greater than 75% of the participants were censored for the endpoint).

Time frame:
Start of treatment to death (up to Week 131)

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR)

DOR was defined for the subset of participants who showed a confirmed CR or PR, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.

Time frame:
First documented response (CR or PR) to disease progression or death (up to Week 131)
Reported as:
Median · weeks
Duration of Response (DOR)
weeksLapatinib 1000 mg + Nab-Paclitaxel
Duration of Response (DOR)48.7 (31.7 to 57.1)
SecondaryTime to Response (TTR)

TTR was defined for the subset of participants who showed a confirmed CR or PR, as the time from the start of treatment until the first documented evidence of CR or PR (whichever status was recorded first).

Time frame:
Start of treatment to first documented response (CR or PR) (up to Week 131)
Reported as:
Median · weeks
Time to Response (TTR)
weeksLapatinib 1000 mg + Nab-Paclitaxel
Time to Response (TTR)7.8 (7.4 to 8.1)
SecondaryTime to Progression (TTP)

TTP was defined as the interval between the start of treatment until the earliest date of disease progression or death due to breast cancer.

Time frame:
Start of treatment to disease progression or death (up to Week 131)
Reported as:
Median · weeks
Time to Progression (TTP)
weeksLapatinib 1000 mg + Nab-Paclitaxel
Time to Progression (TTP)41.0 (39.1 to 64.6)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the start of treatment until the earliest date of disease progression or death due to any cause, if sooner.

Time frame:
Start of treatment to disease progression or death (up to Week 131)
Reported as:
Median · weeks
Progression-Free Survival (PFS)
weeksLapatinib 1000 mg + Nab-Paclitaxel
Progression-Free Survival (PFS)39.7 (34.1 to 63.9)

Adverse events

Collected over Adverse Events (AEs) and Serious AEs were collected from the first study drug dose administration until 30 days after the last dose and recorded on the eCRF, a total period of approximately 9.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib (1000mg) + + Nab-Pacl3/60 (5%)21/60 (35%)60/60 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventLapatinib (1000mg) + + Nab-Pacl
DiarrhoeaGastrointestinal disorders3/60
DehydrationMetabolism and nutrition disorders3/60
AnaemiaBlood and lymphatic system disorders2/60
Febrile neutropeniaBlood and lymphatic system disorders2/60
Left ventricular dysfunctionCardiac disorders2/60
CellulitisInfections and infestations2/60
PneumoniaInfections and infestations2/60
HypokalaemiaMetabolism and nutrition disorders2/60
Acute kidney injuryRenal and urinary disorders2/60
Chest painGeneral disorders1/60
Most frequent other events
Showing 10 of 61
Most frequent other events
EventLapatinib (1000mg) + + Nab-Pacl
DiarrhoeaGastrointestinal disorders53/60
FatigueGeneral disorders41/60
NauseaGastrointestinal disorders39/60
RashSkin and subcutaneous tissue disorders29/60
AlopeciaSkin and subcutaneous tissue disorders24/60
VomitingGastrointestinal disorders23/60
Neuropathy peripheralNervous system disorders23/60
NeutropeniaBlood and lymphatic system disorders22/60
AnaemiaBlood and lymphatic system disorders21/60
Oedema peripheralGeneral disorders16/60

Baseline characteristics

The intent-to-treat (ITT) population comprised of all subjects who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(Years)Lapatinib 1000 mg + Nab-Paclitaxel
Mean56.7 ± 12.78
Age, Customized
Age, Customized(Participants)Lapatinib 1000 mg + Nab-Paclitaxel
<180
18-64 years44
65-84 years16
85+0
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib 1000 mg + Nab-Paclitaxel
Female60
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lapatinib 1000 mg + Nab-Paclitaxel
White50
African American/African Heritage (Her.)6
Asian1
Japanese/East Asian Her./South East Asian Her.1
Native Hawaiian of other Pacific Islander1
American Indian of Alaska Native and White1
08

Study locations

13 sites
  • Novartis Investigative Site
    La Verne, California 91750, United States
  • Novartis Investigative Site
    Long Beach, California 90813, United States
  • Novartis Investigative Site
    Fort Myers, Florida 33916, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30341, United States
  • Novartis Investigative Site
    New York, New York 10065, United States
  • Novartis Investigative Site
    Rochester, New York 14623, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45242, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Richmond, Virginia 23230, United States
  • Novartis Investigative Site
    Salem, Virginia 24153, United States
  • Novartis Investigative Site
    Everett, Washington 98201, United States
  • Novartis Investigative Site
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Yardley DA, Hart L, Bosserman L, Salleh MN, Waterhouse DM, Hagan MK, Richards P, DeSilvio ML, Mahoney JM, Nagarwala Y. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat. 2013 Jan;137(2):457-64. doi: 10.1007/s10549-012-2341-9. Epub 2012 Dec 8. PubMed 23224144 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Jan 2011, 30 months.

Results were first posted in Nov 2011, 10 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 30 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2008
First posted
Jul 3, 2008
StartActual
Jul 2, 2008
Primary completionActual
Jan 5, 2011
CompletionActual
Jan 3, 2018
Results first posted
Nov 22, 2011
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00709761
Responsible party
Sponsor
First posted
Jul 3, 2008
Start date
Jul 2, 2008
Primary completion
Jan 5, 2011
Completion
Jan 3, 2018
Results posted
Nov 22, 2011
Last update
Mar 26, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Albumin-Bound Paclitaxel

Start the discussion